By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Swedish Orphan Biovitrum 


  76  Stockholm  Sweden
Phone: 46-8-697-20-00 Fax: n/a



Company News
Invitation - Presentation Of Sobi's Q1 2017 Results 4/13/2017 11:17:22 AM
Sobi Release: FDA Approves Increased Shelf Life And In-Use Storage At Room Temperature For Orfadin (nitisinone) 3/6/2017 7:37:03 AM
Sobi Receives Approval From The EMA For Higher Capacity Drug Substance Manufacturing For Elocta 3/2/2017 6:24:33 AM
Sobi Enters Into New Distribution Agreement With Valeant (VRX) For Ammonul 2/21/2017 6:40:23 AM
Sobi - Invitation - Presentation Of Sobi's Q4 And FY 2016 Results 2/6/2017 9:50:43 AM
Sobi - Long-Term Safety And Efficacy Data Of Extended Half-Life Therapy Alprolix In Children With Haemophilia B Published In The Lancet Haematology 2/2/2017 6:57:41 AM
Sobi Obtains Approval From The European Commission (EC) For New Dosing Frequency Of Orfadin 2/2/2017 6:49:52 AM
Sobi Release: First Patient Randomized In A Phase II Study Evaluating The Safety And Efficacy Of Anakinra In The Treatment Of Acute Gout 1/11/2017 8:07:41 AM
Sobi And Horizon Pharma (HZNP) Enter Five-Year Distribution Agreement For Ravicti And Ammonaps Outside The United States 12/7/2016 7:31:46 AM
Swedish Orphan Biovitrum AB: Sobi Publishes Its Report For The Third Quarter 2016, Raises Guidance 10/27/2016 11:19:07 AM